NCT04827134View on ClinicalTrials.gov

A Food-effect Study of the Pediatric Dispersible Tablet Formulations of TRIUMEQ® and DOVATO® in Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

May 7, 2021

Primary Completion Date

July 23, 2021

Study Completion Date

July 23, 2021

Conditions
HIV Infections
Interventions
DRUG

TRIUMEQ

TRIUMEQ will be available as fixed dose combination (FDC) dispersible tablets to be administered orally as a dispersion.

DRUG

DOVATO

DOVATO will be available as FDC dispersible tablets to be administered orally as a dispersion.

Trial Locations (1)

78744

GSK Investigational Site, Austin

Sponsors

Lead Sponsor

ViiV Healthcare
All Listed Sponsors
lead

ViiV Healthcare

INDUSTRY